Dr. John Haley, Associate Professor in the Department of Pathology and Director of Developmental Therapeutics in the Cancer Center has agreed to serve as Director of the Proteomics Core.
Dr. Haley earned a Ph.D. in Molecular Endocrinology from the Howard Florey Institute for Experimental Physiology and the University of Melbourne and completed postdoctoral research fellowships at the Howard Florey Institute in Melbourne and at the Imperial Cancer Research Fund and the Ludwig Institute for Cancer Research in London. He returned to the U.S. to join Oncogene Science Inc. as Program Manager for Cancer Therapeutics and was subsequently recruited to OSI Pharmaceutical Inc. in 1992. At OSI, Dr. Haley served as Senior Director for Exploratory Cancer Research, Senior Research Director for Translational and EMT Research, and Senior Research Director for Discovery Research.
Dr. Haley has worked in the area of biological mass spectrometry since 1995, notably pioneering the field of phosphoproteomics from 2000 - 2004. He has published on the exploration of cancer drug resistance and cancer biomarkers, and has organized and chaired several AACR symposia and mini-symposia on the subject. His current expertise is in the quantitation of post-translational modifications coupling stable isotope labeling and mass spectrometry.
